

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

This management discussion and analysis ("MD&A") of the financial condition and results of operations of Liberty Health Sciences Inc., (the "Company" or "Liberty"), is for the three months ended May 31, 2020. It is supplemental to, and should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements and the accompanying notes for the three months ended May 31, 2020 (the "Q1 2021 Financials") as well as the audited consolidated financial statements for the year ended February 29, 2020.

The Company's financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the IFRS Interpretations Committee ("IFRIC") in effect as of and for the year ended February 29, 2020.

This MD&A has been prepared by reference to the MD&A disclosure requirements established under National Instrument 51-102 "Continuous Disclosure Obligations" ("NI 51-102") of the Canadian Securities Administrators, and Staff Notice 51-352 (Revised) – Issuers with US Marijuana Related Activities ("Staff Notice 51-352").

Additional information regarding Liberty Health Sciences Inc. is available on our website at www.libertyhealthsciences.com or through the SEDAR website at www.sedar.com.

This MD&A contains forward-looking information and forward-looking statements within the meaning of Canadian securities laws and United States securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of the Company. In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact and may also constitute forward-looking statements.

Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as of and at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

We use words such as "forecast", "future", "should", "could", "enable", "potential", "contemplate", "believe", "anticipate", "estimate", "plan", "expect", "intend", "may", "project", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant known and unknown risks and uncertainties.

Some of the specific forward-looking statements in this MD&A include, but are not limited to, statements with respect to the following:

- *the intention to grow the business and operations and activities of the Company;*
- *expectations regarding the Company's growing capacity;*
- *the expected performance of the Company's business and operations;*
- *expectations for the effects of COVID-19 on the business' operations and financial condition;*
- *the Company's expectations regarding revenues, expenses and anticipated cash needs;*
- *the build-out of the Company greenhouse infrastructure and the respective costs and timing associated therewith;*
- *the competitive conditions of the industry;*
- *any commentary related to the legalization of cannabis and the timing related thereto;*
- *the applicable laws, regulations and any amendments thereof;*
- *the competitive and business strategies of the Company;*
- *the renewal of licenses;*
- *the framework for the enforcement of medical cannabis and cannabis-related offenses in the United States; and*
- *the grant and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof for any state in which the Company does business.*

Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, general economic and market conditions, investment performance, financial markets, legislative and regulatory changes, technological developments, catastrophic events and other business risks. These forward-looking statements are as of the date of this MD&A and the Company and management assume no obligation to update or revise them to reflect new events or circumstances except as required by securities laws. The Company and management caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made.

LIBERTY HEALTH SCIENCES INC. MANAGEMENT'S DISCUSSION & ANALYSIS

Forward-looking statements may include, but are not limited to, risks and uncertainties related to: business structure risks; legal and regulatory risks inherent in the cannabis industry; financing risks related to additional financing and restricted access to banking; general regulatory and legal risks including risk of civil asset forfeiture; risks relating to anti-money laundering laws and regulations; lack of access to U.S. bankruptcy protections, heightened scrutiny by regulatory authorities; risk of legal, regulatory or political change, general regulatory and licensing risks, limitations on ownership of licenses, regulatory action and approvals from the Food and Drug Administration and risks of litigation; environmental risks including environmental regulation and unknown environmental risks; general business risks including risks related to COVID-19 pandemic, risks of leverage, risks related to the convertible debt, access to capital markets, unproven business strategy, service providers, enforceability of contracts; reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks inherent in an agricultural business; unfavorable publicity or consumer perception, product liability, product recalls, results of future clinical research, difficulty attracting and retaining personnel, dependence on suppliers, reliance on inputs, limited market data and difficulty to forecast, intellectual property risks, constraints on marketing products, fraudulent or illegal activity by employees, contractors and consultants, information technology systems and cyber-attacks, security breaches, reliance on management services agreements with subsidiaries and affiliates, website accessibility, high bonding and insurance coverage, future acquisitions or dispositions; management of growth, performance not indicative of future results and financial projections may prove materially inaccurate or incorrect, conflict of interest; tax risks as well as those risk factors discussed elsewhere in this MD&A and in the Company's Annual Information Form.

The discussion of risk factors in this MD&A has been updated to include discussion of risks related to the current pandemic caused by the spread of the novel coronavirus ("COVID-19"). The nature and scope of the pandemic and its impact are rapidly developing and it is difficult for management to identify at the current time all risks, or quantify those identified, or to assess their impact on particular financial measures and operating results. Nevertheless, discussion under "Risk Factors" identifies potential areas of negative potential impact that may be caused by the pandemic.

The purpose of forward-looking statements is to provide the reader with a description of management's expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this MD&A as well as statements regarding the Company's objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Certain of the forward-looking statements and other information contained herein concerning the cannabis industry, and the general expectations of the Company concerning the industry and the Company's business and operations are based on estimates prepared by the Company using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the cannabis industry involves risks and uncertainties that are subject to change based on various factors.

In this MD&A, reference is made to gross profit before biological asset adjustments, gross margin before biological asset adjustments and adjusted earnings before interest, tax, depreciation and amortization ("EBITDA"), which are not measures of financial performance under IFRS and may not be comparable to similarly titled measures used by other companies. The Company calculates each as follows:

- *Gross profit before biological asset adjustments is equal to gross profit less the non-cash change in the fair value on harvest and less the non-cash change in the fair value on cost of goods sold, if any. Management believes this measure provides useful information as it removes non-cash adjustments required by IFRS to provide greater comparability.*
- *Gross margin before biological asset adjustments is gross profit before biological asset adjustments divided by revenue. Management believes this measure provides useful information as it represents the gross profit based on the Company's cost to produce inventory sold and removes fair value metrics required by IFRS.*
- *Adjusted EBITDA is net income (loss), plus (minus) income taxes (recovery), plus (minus) foreign exchange loss (gain), plus (minus) change in fair value of embedded derivative, plus interest accretion, plus share-based compensation, plus depreciation, plus interest expense, plus change in fair value of biological assets, plus change in fair value in cost of goods sold, as determined by management. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as is a close proxy for repeatable cash generated by operations.*

All amounts in this MD&A are expressed in Canadian dollars, unless otherwise indicated.

This MD&A is prepared as of July 30, 2020.

COMPANY OVERVIEW

Liberty Health Sciences Inc. is a producer and retailer of cannabis products aimed at improving the quality of peoples' lives. Liberty's focus is solely on the United States market where it produces high-quality products at a low cost. Through its wholly owned subsidiary, DFMMJ Investments, LLC (d/b/a Liberty Health Sciences Florida) ("Liberty Florida"), Liberty is licensed to produce and sell medical cannabis products in Florida. The Company is focused on acquiring other cannabis business and expanding its operations throughout the United States.

Liberty's common shares (the "Common Shares") are listed under the symbol "LHS" on the Canadian Securities Exchange ("CSE") and the OTC Markets OTCQX Best Market ("OTCQX") in the United States under the symbol "LHSIF".

Liberty was incorporated under the Business Corporations Act (British Columbia) (the "BCBCA") on November 9, 2011 as SecureCom Mobile Inc. ("SecureCom"). On July 20, 2017, 1006397 B.C. Ltd. ("Subco"), a British Columbia Company and wholly-owned subsidiary of SecureCom, completed a business combination (the "Business Combination") with DFMMJ Investments, Ltd. ("Holdco") whereby SecureCom acquired all of the issued and outstanding shares of Holdco by way of a three-cornered amalgamation. Holdco amalgamated with Subco under the BCBCA to form a wholly owned subsidiary of SecureCom named "Liberty Health Sciences USA Ltd.". Concurrently with the Business Combination, SecureCom changed its name to "Liberty Health Sciences Inc.".

STRATEGY AND OUTLOOK

Liberty's business strategy is to acquire and operate cannabis operations in the United States in those states that are heavily populated with limited licenses. The Company is currently active in Florida. In the U.S., thirty-three states have legalized the use of medical cannabis for patients with certain qualifying conditions. In most of these medical states, a regulatory framework is in place whereby patients can receive a recommendation from a certified physician to purchase medical cannabis in approved dispensaries.

Liberty has the know-how and expertise to transform targeted investments into low-cost operations that produce high quality cannabis products while delivering value to its shareholders. Liberty has established strong relationships with producers of topicals, transdermal products, vaporizers, concentrates, and extracts in Florida and will pursue business opportunities in other states where possible.

Florida Operations

Florida's medical cannabis program was introduced in June 2014 when the Florida Legislature passed the Compassionate Medical Cannabis Act of 2014 ("CMCA").

The CMCA permitted low-THC cannabis oils to be dispensed and purchased by patients suffering from cancer and epilepsy. Under this program, six organizations called Dispensing Organizations were licensed to dispense low-THC cannabis to patients.

In November 2016, Florida voters approved the Amendment 2, the Florida Medical Marijuana Legalization Initiative, ballot measure with 71% of the vote. This constitutional amendment expanded the program by allowing the production of medical marijuana with unlimited THC levels.

In June 2018, Governor Scott signed Senate Bill 8-A: "Medical Use of Marijuana," which outlined how patients can qualify and receive medical cannabis under the state's constitutional amendment. The bill also increased the number of available MMTC licenses to 17, with 14 of these licenses issued as of the end of 2018. In April 2019, as the result of a joint settlement, the state awarded additional licenses, and as of the date hereof a total of 22 licenses have been granted in the state.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

A single MMTC license allows for the cultivation, processing, and dispensing of cannabis products. Originally, each MMTC was permitted to open up to 25 dispensaries statewide. With each additional 100,000 qualified patients, the dispensary cap increased by five for each MMTC. However, the limit on dispensaries expired in April of 2020. There is now no limit on the number of facilities a MMTC may operate.

Permitted products originally included oil-based formulations. Rules permitting the sale of edible medical cannabis products are under development.

In May 2018, a district court judge ruled that Florida's medical cannabis constitutional amendment requires the Department of Health to permit sales of smokable medical cannabis flower. Smokable flower was introduced as a permitted form factor in March 2019, shortly after Governor DeSantis signed a bill that repealed the state's ban on smokable medical cannabis flower.

Each MMTC is required to cultivate and process all medical cannabis products they dispense. Wholesale transactions are prohibited absent a demonstrated crop failure. Home delivery is permitted.

The Company holds a vertically-integrated medical cannabis license issued in the state.

In the State of Florida, Liberty completed the cultivation portion of its retrofit activities at its 387-acre Liberty 360 Innovation Campus ("Liberty 360") property in March 2019, bringing 190,000 square feet of greenhouses online. The cultivation production capacity of the Company is currently approximately 19,500 kgs annually (wet weight), and the Company made further investments in fiscal 2020 to increase its plant yield, targeting an increase of production of approximately 25% in 2021. Retrofit activities associated with adding additional drying rooms to processing continued through fiscal 2020. The Company is also investing into infrastructure for ethanol extraction in order to increase its oil processing efficiency significantly, in addition to adding an industrial kitchen in preparation for the legalization of edible cannabis products.

Liberty has opened 26 dispensaries to date throughout Florida, with 23 dispensaries opened by fiscal year end. The Company has lease agreements in place for another ten locations and is further negotiating another seven. Liberty has plans to have 35 dispensaries by the end of fiscal 2021. To better serve Florida's expanding patient base, Liberty also provides free door-to-door delivery services out of several of its dispensaries.

Liberty continues to expand its product offerings and has added several new brand relationships through February 2020 to offer greater choice to its patients. Liberty currently works with best-in-class brands to bring vaporizer hardware, concentrates, topicals, pre-rolled cannabis cigarettes and other product lines to supplement its own house brand product lines. With the positive reaction to the Company's rollout of whole flower products, Liberty expects its sales to continue to grow steadily as it expands its dispensary reach and product offerings.

IMPACT OF COVID 19

COVID-19 started to develop toward the end of our fiscal year, with the first confirmed cases of coronavirus being detected in Florida on March 1.

As at May 31, 2020, the Company asset carrying values were not impaired due to coronavirus.

Subsequent to the fiscal year end, despite the numbers of confirmed cases continuing to increase, as at March 31, 2020, due to Liberty deemed an essential business, the Company's dispensaries continued to operate, albeit not without challenges. Like many other business, external pressures such as family care, childcare closings, school closings, etc. has caused numerous employees to take leave which has slightly affected our business.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

During the month of April, there was one case of Coronavirus detected in one of our dispensaries in Orange Park, resulting in the store being temporarily closed so that it could be disinfected, and personnel in that store were quarantined.

As a result of the above challenges, the Company is actively recruiting talent from other industries in order to continue assisting the communities the Company serves in Florida at this critical time, as communities are deeply affected due to the pandemic.

Liberty continues to strive to provide services to its patients, and under the guidelines of the Governor of Florida, the State Surgeon General, and the Florida Department of Health, the Company intends to keep its dispensaries open unless deemed necessary in order to protect the safety of our patients and employees.

More generally, also as a result of the coronavirus pandemic, the Company has strategically delayed its store openings. Other strategic actions included the temporary lifting of our delivery fees until further notice and offering curbside pickup.

While the coronavirus pandemic is rapidly evolving and there are many factors for which the impacts are unknown, management continues to assess the situation on a daily basis. To date, being an essential business serving the medical needs of its patients, the Company's business has proven to be more resilient than other sectors in this pandemic.

Barring any significant changes for which management might not have control, management considers that it is reasonably likely to expect the business to continue showing the resilience it has shown in the first months of the coronavirus crisis.

Under current conditions, management expects that the Company will be able to meet its contractual obligations including servicing interest payments on its outstanding debt, meeting the payment obligations of its lease financing arrangements, paying its suppliers and payroll.

As of this date, the Company does not have any material receivable balances that are impaired other than the promissory note receivable for which the Company reported a provision in fiscal Q4 2019 and for which it continues in its recovery efforts.

Subsequent to February 29, 2020 financial markets have been negatively impacted by the novel Coronavirus or COVID-19, which was declared a pandemic by the World Health Organization on March 12, 2020. Looking forward, COVID-19 has resulted in significant economic uncertainty and consequently, it is difficult to reliably measure the potential impact of this uncertainty on our future financial results.

HIGHLIGHTS

Rollout of Liberty Health Sciences Dispensaries

Liberty Florida is licensed to operate as a Medical Marijuana Treatment Center ("MMTC") under applicable Florida law and to possess, cultivate, process, dispense and sell medical marijuana in the State of Florida pursuant to the terms of the license (the "Florida License") issued by the Florida Department of Health, Office of Medical Marijuana Use (the "Florida Department") under the provisions of the *Senate Bill 8A, Fla. Stat. 381.986 et seq* (the "Florida Legislation"). The Company opened its inaugural dispensary in January 2018 in the Villages community in north-central Florida and opened an additional nine dispensaries during the fiscal 2019 year. During the first quarter of fiscal 2020, Liberty opened four more dispensaries, bringing its total dispensary count to 14 at May 31, 2019. During the second quarter of fiscal 2020, the Company opened another two dispensaries, increasing total dispensary count to 16 as at August 31, 2019. During the third quarter of fiscal 2020, Liberty opened another three dispensaries, increasing total dispensary count to 19 at November 30, 2019.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

During the fourth quarter of fiscal 2020, the Company opened another four dispensaries, increasing total dispensary count to 23 as at February 29, 2020. Subsequent to year end, the Company opened an additional three dispensaries, increasing total dispensary count to 26 to date. The Company has also signed leases for another ten dispensary locations across Florida and is under negotiations for another seven. The Company plans to have thirty-five dispensaries by the end of fiscal 2021, all subject to local municipal permitting and approval by the Florida Department.

Patient Growth

The medical cannabis marketplace in Florida is in its early stages, which is evidenced by the fact that approximately 367,592 active patients have been added to the Medical Marijuana Use Registry as of June 26, 2020 statewide. With over 20 million residents, Florida's potential patient base is vast. The patient registration volume has grown significantly in recent months as more supply has become available and as access to the growing number of physicians who are qualified to recommend medical cannabis has expanded, which has significantly increased the number of registered patients since the beginning of 2018. There are now over 2,484 qualified physicians in the State of Florida who can access medical cannabis for their patients. Patient volume is expected to continue increasing at a rapid pace considering the expanded medical uses as well as the broad availability of high THC products, and the introduction of smokable flower products to the Florida market. With expanded production capabilities, a primary goal of the business moving forward is the acquisition of qualified patients.

Product Offerings

Liberty announced several licensing and distribution agreements through fiscal 2019 and 2020, including the following:

The Company announced in May 2018 that an amended licensing agreement was signed with Aphria Inc. ("Aphria") to add Solei Sungrown Cannabis to the Company's growing list of brands in the state of Florida. In August 2018, the Florida Department of Health approved the Solei line of products for sale. Aphria's RIFF line of products was subsequently approved by the Florida Department of Health in October 2018. Subsequent to the termination of the Company's agreements with Aphria in October 2018, Liberty phased out its Solei and RIFF products. The Company's Aphria branded products, as well as Liberty's own house brand products, were also regrouped and rebranded under the Zentient and Pretty Pistil brand names in June 2019.

In September 2018, Liberty announced that it had signed an agreement with PAX Labs Inc. to distribute the award-winning PAX Era cannabis oil vaporizer in Florida. A variety of strains have been released under Liberty's licensed brands for use in the PAX Era device, including Mary's Medicinals.

In December 2018, the Company announced the launch of Zentient Labs, a line of premium, hemp-based CBD products. Zentient Labs includes a line of products across numerous categories including an athletic line, a wellness line, a beauty line, and a pet products line.

In March 2019, the Company announced a license agreement with the Werc Shop, a scientific consulting group recognized for its expertise in cannabis terpene analysis and terpene-based formulations. Liberty expects to leverage this partnership to create formulations for its Zentient and Pretty Pistil in-house brands, announced in June 2019.

In June 2019, the Company announced new partnerships with Papa's Herb™ and Lemon and Grass. Papa's Herb™ is a line of accessibly priced, THC smokable flower products, including pre-rolls and whole flower. The Lemon and Grass brand offers a portfolio of cannabis pain relief products, expanding Liberty's oral and topical product lines.

In December 2019, the Company announced a new partnership by which it is expanding its product

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

offerings by introducing the G Pen product line of personal, portable devices in all its dispensaries. Greenco Science, the maker of the G Pen Gio, Pro, Connect, Elite and Nova, is a leader in engineering advanced cannabis vaporizers, known for its aesthetics, portability, functionality, and user experience.

In March 2020, the Company announced a new partnership by which it is expanding its product offerings by introducing the Clarity product line of closed system pods, and inhalation cartridges, etc. in all of its stores.

In April 2020, the Company also announced it had recently introduced the all-new Papa's Herb classic 510 Cartridge pen to its Papa's Herb line, further extending its popular offering of G Pen devices which now includes Roam, Elite, Connect, Gio, Pro, and Nova.

In June 2020, the Company announced it will launch DomPen in all its locations, extending the Company portfolio of top-selling vape pens.

With the latest additions to the brand portfolio, products under the Liberty umbrella include:

Clarity Brands: Clarity Brands promotes the clarification of body and soul through the use of cannabis products that are lab tested and organically and locally farm grown.

Zentient: Zentient™ represents a line of premium CBD and THC balanced products including topicals, vapes, and oral solutions made from a proprietary formula of ultra-high-quality cannabinoids.

Pretty Pistil: Pretty Pistil is a powerful (feminine house brand) that brings a beautifully balanced approach to high quality cannabis experiences for those with sophisticated tastes and a rebellious spirit.

Papa's Herb: Papa's Herb™ specializes in providing value products to the market. The brand is hyper-focused and prioritizes their customers first. They offer quality Flower products at an always accessible price-point for all to enjoy.

Mary's Medicinal: Best known as the developer and exclusive distributor of the award-winning Transdermal Cannabis Patch, Mary's is transforming how people view and utilize cannabis; developing products that maximize the benefits of cannabinoids, terpenes, and other plant nutrients.

G Pen: Greenco Science®, the maker of the G Pen Gio, Pro, Connect, Elite and Nova, is a leader in engineering advanced cannabis vaporizers, known for its aesthetics, portability, functionality, and user experience.

PAX: PAX is a leader in the design and development of premium cannabis vaporization technologies and devices.

Lemon and Grass: Lemon and Grass combines nature, science, and tech to formulate, and deliver, the highest standard of product. We strive for consistency to ensure that each and every time you use Lemon and Grass products, the results are reliable.

DomPen: DomPen is one of California's top vaporizer brands, best known for its affordable all in one vaporizers and Dom cartridges, which offer a range of popular strains that patients in other states have trusted for years.

Honey®: Honey® revolutionized the cannabis industry by becoming the first producer in the world to market distilled cannabis oil in vape cartridges. Today, they provide authentic, full spectrum oil in vape cartridges, applicators, and caps to legal dispensaries and delivery services.

The Company has several hardware and product licensing agreements under negotiation and expects to announce these partnerships as they materialize.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

In its continued efforts to protect the public, the U.S. Food and Drug Administration (FDA) is strengthening its warning to consumers to stop using vaping products containing THC, amid more than 1,000 reports of lung injuries following the use of vaping products. The FDA is working closely with the U.S. Centers for Disease Control and Prevention (CDC), as well as state and local public health partners to investigate these illnesses as quickly as possible.

Certain of these offerings may be subject to approval by state authorities. The Company continues to round out its product line, offering THC and CBD products in several consumable formats.

Other Updates

Recently adopted standards and interpretations

The Company implemented the following standards and interpretations for the year ended February 29, 2020:

IFRS 16 – In January 2016, the IASB issued IFRS 16 Leases, which replaced IAS 17 Leases. This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term of more than twelve months unless the underlying asset is of low value. As a lessee, the Company will be required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments.

Substantially all the Company's operating leases are real estate leases for dispensaries. As a lessee, the Company has now recognized right-of-use assets and lease liabilities primarily for its operating leases of real estate properties. The depreciation expense on right-of-use assets and interest expense on lease liabilities will replace rent expense, previously recognized on a straight-line basis.

For leases where the Company is the lessee, it had the option of adopting a fully retrospective approach or a modified retrospective approach on transition to IFRS 16. The Company has adopted the standard on March 1, 2019 using the modified retrospective approach. The modified retrospective approach applies the requirements of the standard retrospectively with the cumulative effects of initial application recorded in opening retained earnings as at March 1, 2019, and no restatement of the comparative period. Under the modified retrospective approach, the Company chose to measure all right-of-use assets retrospectively as if the standard had been applied since lease commencement dates.

IFRS 16 permits the use of exemptions and practical expedients. The Company applied the following recognition exemptions and practical expedients:

- grandfather lease definition for existing contracts at the date of initial application;
- exclude low-value and short-term leases from IFRS 16 lease accounting;
- use portfolio application for leases with similar characteristics, such as vehicle and equipment leases;
- apply a single discount rate to a portfolio of leases with reasonably similar characteristics at the date of initial application;
- exclude initial direct costs from the measurement of the right-of-use assets at the date of initial application;
- use hindsight in determining lease term at the date of initial application; and
- assume an incremental borrowing rate of 15%-16%, determined on corresponding remaining term.

As a result of the initial application of IFRS 16 as at March 1, 2019, Management recognized \$14,697,378 of right-of-use assets and \$14,008,700 of lease liabilities on its consolidated statements of financial position, with the difference recorded in opening retained earnings for the year.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

Sale of Chestnut Farm & Ohio Joint Venture Interest

On August 13, 2019, the Company entered into a definitive asset purchase and sale agreement to sell its Chestnut Hill Tree Farm ("CHT") facility in Florida and certain joint venture interest and dispensary licenses in Ohio for cash consideration totaling USD\$14,750,000 (CAD\$19,523,100) (the "Disposition"), of which USD\$14,650,000 (CAD\$19,390,740) corresponded to the CHT facility and USD\$100,000 (CAD\$132,360) to the Investment in Ohio JV. Pursuant to the Disposition, the Company recognized a gain on sale of the CHT facility of \$14,266,807. The following summarizes the gain on the sale of CHT:

Property, plant and equipment	\$	5,536,871
Accumulated depreciation		(653,541)
Total assets, net		4,883,330
Proceeds on disposition, gross		19,390,740
Transaction costs		(240,603)
Proceeds on disposition, net		19,150,137
Net gain on sale	\$	14,266,807

In August 2019, the Company entered into Membership Interest Redemption agreements with the Schottenstein Group and dissolved, 50.1% of Schottenstein Aphria I, LLC, 50% of Schottenstein Aphria II, LLC, and 50% of Schottenstein Aphria III, LLC. The Company received proceeds of \$132,360 and was released of all outstanding balances to/from the Ohio JV.

The following summarizes the (loss) on the redemption of Ohio JV:

		Amount
Balance as at February 28, 2018	\$	-
Contributions		816,273
Share of loss		(578,362)
Effect of foreign exchange		2,282
Balance as at February 28, 2019	\$	240,193
Contributions		142,427
Share of loss		(166,916)
Proceeds from redemption of JV		(132,360)
Release of outstanding to/from JV		(90,450)
Effect of foreign exchange		7,106
Balance as at February 29, 2020	\$	-

The total loss on investment in Ohio JV for the year ended February 29, 2020 was \$166,916.

SELECTED OPERATIONAL AND FINANCIAL RESULTS

	Three months ended May 31, 2020	Three months ended May 31, 2019
Operating performance		
Grams harvested	2,355,780	532,445
Equivalent grams sold	1,179,431	462,057
Average realized price per gram	\$ 10.18	\$ 11.95
Active registered patients	38,129	13,042
Number of SKUs	277	97
Average transaction size (\$)	\$ 98	\$ 98
Number of dispensaries open	23	15
Number of hubs open	7	6
Financial performance		
Revenue, net of discounts	\$ 18,440,756	\$ 5,520,561
Gross profit before fair value biological asset adjustments	10,700,996	2,209,093
Gross margin after fair value biological asset adjustments	19,246,177	5,018,399
Net Income (loss) before tax	9,505,535	(3,202,696)
Net Income (loss) per share	0.01	(0.01)
Adjusted EBITDA (defined below)	4,583,269	(3,606,849)
Cash and term deposits	30,961,904	5,415,538
Capital assets	80,719,381	75,649,537
Total assets	214,466,285	154,117,327
Total non-financial liabilities	12,223,450	1,424,717
Shareholders' equity	148,835,830	113,648,638

RESULTS OF OPERATIONS

Revenue

Revenue, net of discounts, for the three months ended May 31, 2020 was \$18,440,756, compared with \$5,520,561 for the three months ended May 31, 2019. The significant year-over-year increase in revenue was driven by the Company's year-over-year increase of dispensaries locations, the increase in its product count, the increase in smokable flower sales, and the increase in the registered patient base on the Medical Marijuana Use Registry in Florida.

Gross profit and gross margin

For the three months ended May 31, 2020, gross profit after biological asset adjustments was \$19,246,177, compared with \$5,018,399 for the three months ended May 31, 2019. Included in gross profit for the three months ended May 31, 2020 are unrealized gains (losses) from fair value changes on the growth of biological assets of \$9,118,888, partially offset by realized fair value amounts included in costs of inventory sold of 573,707, amounts that are non-cash fair value adjustments made following IFRS.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

The gross profit for the Company is outlined below for the following periods:

	Three months ended May 31, 2020	Three months ended May 31, 2019
Revenue, net of discounts	\$ 18,440,756	\$ 5,520,561
Costs of sales		
Cost of goods sold, net	7,739,760	3,311,468
Realized fair value amounts included in cost of goods sold	573,707	1,506,243
Unrealized fair value gain on growth of biological assets	(9,118,888)	(4,315,549)
Total Cost of Sales	\$ (805,421)	\$ 502,162
Gross profit	\$ 19,246,177	\$ 5,018,399

Gross profit after biological asset adjustments for the three months ended May 31, 2020 increased to \$19,246,177, compared with \$5,018,399 for the three months ended May 31, 2019.

The increase in gross profit before biological asset adjustments reflects an increase in revenue from a higher number of customers, a larger product selection and additional dispensaries to assist in distribution, as well as a higher gain from fair value adjustments on the growth of biological assets. Liberty's cost of goods sold has also increased significantly, reflecting higher depreciation from a new greenhouse infrastructure, higher direct labor costs in respect of cultivation and processing and associated overheads.

Cost of sales currently consists of three main categories: (i) cost of goods sold, net; (ii) realized fair value amounts included in cost of goods sold; (iii) change in fair value on growth of biological assets.

(i) Cost of goods sold, net include the direct cost of materials and labor related to the medical cannabis sold. This includes the costs of any purchased medical cannabis in the event of an acquisition of an existing license, growing, cultivation and harvesting costs, quality assurance and quality control, cannabis oil processing costs, packaging, labelling, and maintenance and repairs of production equipment and greenhouse infrastructure utilized in the production of medical cannabis. Cost of goods sold, net also includes depreciation that relates to production equipment and greenhouse infrastructure utilized in the production of medical cannabis, and certain overhead costs related to the company production operations.

(ii) Realized fair value amounts included in cost of goods sold are the amount of fair value adjustments of biological assets that have been included in inventory and sold during the year.

(iii) Fair value adjustment of biological assets is part of the Company's cost of sales under IFRS reporting standard IAS41: *Agriculture* relating to agriculture and biological assets (i.e. living plants). This line item represents the effect of the non-cash fair value adjustment of biological assets (medical cannabis) produced in the period.

Management believes that the use of non-cash IFRS adjustments in calculating gross profit and gross margin does not represent the true underlying economics of the business due to the large value of non-cash fair value adjustments required. Accordingly, management believes the use of gross profit before biological asset adjustments and gross margin before biological asset adjustments provides better representation of performance by excluding non-cash adjustments required by IFRS.

Gross profit before biological asset adjustments and gross margin before biological asset adjustments are non-GAAP financial measures that do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

The table below shows the reconciliation from gross profit before fair value adjustments to gross profit:

	Three months ended May 31, 2020	Three months ended May 31, 2019
Revenue, net of discounts	\$ 18,440,756	5,520,561
Cost of goods sold, net	7,739,760	3,311,467
Gross profit before biological asset adjustments	\$ 10,700,996	\$ 2,209,093
Gross margin before biological asset adjustments	58.0%	40.0%
Add back:		
Realized fair value adjustments included in cost of goods sold	(573,707)	(1,506,243)
Unrealized fair value gain on growth of biological assets	9,118,888	4,315,549
Subtotal fair value adjustments	\$ 8,545,181	\$ 2,809,306
Gross Profit	\$ 19,246,177	\$ 5,018,399

The increase in gross profit before biological asset adjustments reflects an increase in revenue from a higher number of customers, a larger product selection and additional dispensaries to assist in distribution.

Liberty's cost of goods sold has also increased significantly, reflecting higher depreciation from a new greenhouse infrastructure, higher direct labor costs in respect of cultivation and processing and associated overheads.

The increase in gross profit results (i) from an increase in gross profit before biological asset adjustments as well as (ii) from a higher gain from fair value adjustments on the growth of biological assets partially offset by realized fair value adjustments included in the cost of goods sold.

Operating expenses

	Three months ended May 31, 2020	Three months ended May 31, 2019
Operating expenses		
Professional fees	\$ 953,098	\$ 931,268
Employee and staff costs	791,217	1,056,139
Office and general	1,071,349	834,032
Consulting fees	40,597	75,364
Travel and entertainment	48,429	78,506
Advertising and marketing	119,233	285,867
Insurance	344,580	321,774
Selling costs	2,265,123	1,344,472
Facilities expenses and leases	220,154	217,058
Royalty	498,258	300,186
Depreciation	965,230	647,945
Amortization	32,214	99,665
Share-based compensation	417,499	1,292,672
Total operating expenses	\$ 7,766,981	\$ 7,484,948

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

Operating expenses for the three months ended May 31, 2020 were \$7,766,981, compared with \$7,484,948 for the three months ended May 31, 2019.

The primary drivers of operating costs were i) selling costs driven by retail and delivery costs; ii) professional fees consisting primarily of legal, lobbying, advisory and audit fees; iii) office and general, driven by larger facility (Liberty 360) and additional dispensaries; iv) royalty expense, driven by increased sales of licensed products by the Company; v) depreciation driven by larger greenhouse infrastructure facility and additional dispensaries; and vi) insurance expense. Partially offsetting the increase in operating expenses from the above mentioned drivers, compared to the same period last year Liberty's had lower employee and staff costs relating to executive and administrative personnel of \$791,217; lower share-based compensation expense related to stock options of \$417,499, lower advertising and marketing expense of \$119,233, and lower travel and entertainment expense of \$48,429.

Non-operating (income) expense

	Three months ended May 31, 2020	Three months ended May 31, 2019
Non-operating (income) expense		
Other (income) expense	\$ (254,151)	\$ 54,985
Gain from sale of Chestnut Hill Tree Farm	-	-
Change in fair value of investments	-	52,844
Interest expense	1,051,950	956,327
Loss on redemption of joint venture	-	68,999
Application costs	-	-
RTO Transaction costs	-	-
Investor relations and filing fees	19,840	234,408
Loss on settlement of liability	-	-
Provision on promissory note	-	-
Impairment of intangible asset	-	-
Interest accretion	733,053	592,391
Change in fair value of embedded derivative	(36,119)	(1,397,723)
Foreign exchange loss (gain)	459,088	173,916
Total non-operating income (expense)	\$ 1,973,661	\$ 736,147

The Company's non-operating (income) expense for the three months ended May 31, 2020 increased to \$1,973,661, compared with \$736,147 for the three months ended May 31, 2019.

During the three months ended May 31, 2020, Liberty incurred non-operating costs primarily in respect of: i) interest expense and interest accretion related to its convertible debt and to the Company's dispensary lease liabilities; and ii) higher foreign exchange loss. In addition, compared to the three months ended May 31, 2019, the Company had a lower non-cash gain in the fair value of the embedded derivative associated with its convertible debt, which was driven by changes in the Company's share price, lower time to maturity and changes in the discount rate. Finally, during the three months ended May 31, 2020, the Company recorded other (Income) expense of (\$254,151). The higher other (income) expense compared to the same period last year was partially explained by higher income associated with the sale of timber.

Net Income (loss)

The Company recorded net income (loss) for the three months ended May 31, 2020 of \$4,217,682 or \$0.01 per basic share (\$0.01 per diluted share), which includes an unrealized gain from fair value changes on the growth of biological assets that is recorded under IFRS. These results compare with a net loss of (\$3,202,696) or (\$0.01) per share for the three months ended May 31, 2019. The year-over-year increase

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

in the Company's net income was driven by: i) the Company's year-over-year increase in revenue resulting from the opening of new dispensaries and delivery locations, the increase in its product count, and the increase in the registered patient base on the Medical Marijuana Use Registry in Florida; ii) fair value changes on the growth of biological assets partially offset by adjustments to the realized fair value amounts included in the cost of inventory sold; iii) lower share-based compensation expense compared to the same period last year; iv) partially offset by the increase in cost of goods sold, by higher selling costs, higher interest expense, higher depreciation expense, and higher operating costs associated with the Company's Liberty 360 facility and its dispensary operations.

Comprehensive Income

The Company recorded other comprehensive income for the three months ended May 31, 2020 of \$4,565,048, compared with \$3,171,238 for the three months ended May 31, 2019. Other comprehensive income is a result of the Company's wholly owned subsidiary Liberty Health Sciences, LLC using the United States dollar as its functional currency, and the changes in the US dollar to Canadian dollar exchange rate during the period. The closing foreign exchange rates (United States dollar stated in Canadian dollars) for the relevant presentation dates were as follows: May 31, 2020 – 1.3787, February 29, 2020 – 1.3429, May 31, 2019 – 1.3527.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

The Company management uses this non-IFRS financial measure, and believes that it enhances an investor's understanding of the Company's financial and operating performance from period to period.

The Company calculates Adjusted EBITDA as net income (loss) adjusted for: unrealized gains resulting from fair value changes on growth of biological assets, realized fair value amounts included in the cost of inventory sold, income taxes, foreign exchange, interest expense, interest accretion, change in fair value of embedded derivative, share-based compensation, depreciation and amortization, and certain one-time items as determined by management.

The table below reconciles net Income (loss) to Adjusted EBITDA for the three months ended May 31, 2020 and compares it to Adjusted EBITDA for the three months ended May 31, 2019, as follows:

	Three months ended May 31, 2020	Three months ended May 31, 2019
Net Income (loss)	\$ 4,470,003	\$ (3,202,696)
Adjustments		-
Income tax	5,035,532	-
Foreign exchange loss (gain)	459,088	173,916
Change in fair value of embedded derivative	(36,119)	(1,397,723)
Interest accretion	733,053	592,391
Share-based compensation	417,499	1,292,672
Depreciation	965,230	647,945
Amortization	32,214	99,665
Interest expense	1,051,950	956,327
Change in fair value of biological assets	(9,118,888)	(4,315,549)
Fair value adjustments in cost of goods sold	573,707	1,506,243
Adjusted EBITDA	\$ 4,583,269	\$ (3,646,809)

SELECTED QUARTERLY RESULTS

The following table sets out certain financial information for the past eight fiscal quarters:

Selected Quarterly Results	Three months ended May 31, 2020	Three months ended February 29, 2020	Three months ended November 30, 2019	Three months ended Aug 31, 2019
Revenue	\$ 18,440,756	\$ 17,805,108	\$ 16,122,254	\$ 10,627,655
Net Income (loss)	\$ 4,217,682	\$ (4,306,958)	\$ 6,891,716	\$ 22,884,261
Net comprehensive Income (loss)	\$ 8,782,730	\$ (2,345,749)	\$ 6,976,958	\$ 20,778,009
Net Income (loss) per share – basic and diluted	\$ 0.01	\$ (0.01)	\$ 0.02	\$ 0.07
Selected Quarterly Results	Three months ended May 31, 2019	Three months ended February 28, 2019	Three months ended November 30, 2018	Three months ended August 31, 2018
Revenue	\$ 5,520,561	\$ 3,470,033	\$ 3,172,097	\$ 2,219,290
Net Income (loss)	\$ (3,202,696)	\$ (2,768,313)	\$ (9,698,829)	\$ (5,605,355)
Net comprehensive Income (loss)	\$ (31,458)	\$ (6,080,721)	\$ (5,619,989)	\$ (5,075,718)
Net Income (loss) per share – basic and diluted	\$ (0.01)	\$ (0.02)	\$ (0.03)	\$ (0.02)

LIQUIDITY AND CAPITAL RESOURCES

The Company monitors its capital structure and manages its cash flows to assess the liquidity necessary to fund its operations and activities. As at May 31, 2020, Liberty maintained \$30,961,904 of cash and cash equivalents on hand, compared to \$24,957,245 in cash and cash equivalents as at February 29, 2020.

For the three months ended May 31, 2020, cash provided (used) by operational activities was \$11,158,541, which compares to cash provided (used) by operational activities of (\$4,679,153) for the three months ended May 31, 2019.

For the three months ended May 31, 2020, cash provided (used) by investing activities was (\$4,324,234) which compares to cash provided (used) by investing activities of (\$1,765,341) for the three months ended May 31, 2019. Key factors driving cash provided (used) by investing activities included capital expenditures required for new dispensary buildouts and production equipment.

For the three months ended May 31, 2020, cash provided (used) by financing activities was (\$1,051,989), which compares to cash provided by financing activities during the three months ended May 31, 2019 of (\$956,327). The year over year variance is driven by higher interest expense associated with lease liabilities partially offset by lower interest payments associated with the Company's convertible debt during the three months ended May 31, 2020, as compared to that in the three months ended May 31, 2019.

Working capital is a common measure of a Company's short-term financial health and its ability to meet its upcoming operational and capital requirements. As May 31, 2020, the Company maintained working capital of \$50,113,117, including the impact on inventory and biological assets from the fair value adjustments on the growth of biological assets. Management believes that it will have enough positive operating cash flow and funds available on hand to meet its operational goals over the next fiscal year. Liberty expects its sales to continue to grow at a steady rate as it expands its dispensary reach and cannabis offerings in its dispensaries. Although the Company anticipates that it will have positive cash flow from operating activities in future periods, to the extent that the Company has negative cash flow in any future period, the Company may be required to take additional measures to increase its liquidity and capital resources, including

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

obtaining additional equity or debt financing.

COMMITMENTS AND CONTINGENCIES

The Company has been served a summons in a class action lawsuit against the Company and certain of its former officers and a former director. These claims relate to alleged violations of federal securities laws.

In the ordinary course and conduct of its business, the Company is occasionally the subject of litigation in employment and property matters.

With the exception of the first-mentioned action, none of the matters represent material exposure to the Company.

As at May 31, 2020 and February 29, 2020, the Company's statement of financial position reflects a provision of \$176,000 related to these contingencies which is Management's estimate of the cost of these actions. The Company intends to vigorously defend itself in this action.

SHARE CAPITAL

Liberty has the following securities issued and outstanding, as at the date of this MD&A:

	Presently outstanding	Exercisable	Exercisable & in- the-money *	Fully diluted
Common shares	346,090,635	n/a	n/a	346,090,635
Warrants	9,407,661	9,407,661	0	9,407,661
Stock options	5,517,496	2,550,823	1,176,667	5,517,496
Fully diluted as at May 31, 2020	361,015,792	11,958,484	1,176,667	361,015,792

RELATED PARTY BALANCES AND TRANSACTIONS

Key management personnel are those persons that have the authority and responsibility for planning, directing and controlling the activities of the Company directly and indirectly. Key management personnel include the Company's directors and certain members of the senior management group.

For the three months ended May 31, 2020, the Company paid \$539,869 to key management personnel and related parties. This compares to \$830,904 paid to related parties in the three months ended May 31, 2019. The amounts paid to related parties in the three months ended May 31, 2020, and May 31, 2019 are broken down as follows:

	Three months ended May 31, 2020	Three months ended May 31, 2019
Employee and staff costs	\$ 161,458	\$ 193,155
Share-based compensation	333,471	516,684
Consulting and Director Fees	44,940	44,565
Interest on convertible note	-	76,500
Total	\$ 539,869	\$ 830,904

Employee and staff costs, professional fees, share-based compensation and termination payments were payments made in respect of employment agreements of directors and officers of the Company and family members related to them. Share-based compensation expense includes the impact of the accelerated vesting of stock options for certain directors and officers.

Consulting fees include \$13,828 incurred during the year ended May 31, 2020 with a shareholder who exercises significant influence over the Company, compared to consulting fees of \$5,841 incurred with a shareholder who exercises significant influence for the three months ended May 31, 2019.

ISSUERS WITH U.S. CANNABIS-RELATED ACTIVITIES

On February 8, 2018, the Canadian Securities Administrators revised their previously released Staff Notice 51-352 *Issuers with U.S. Marijuana-Related Activities* (the "Staff Notice") which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the United States as permitted within a particular state's regulatory framework. All issuers with United States cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in prospectus filings and other required disclosure documents.

As a result of the Company's existing operations and recent acquisitions in the United States, Liberty is properly subject to the Staff Notice and accordingly provides the following disclosures:

Nature of Involvement

As at May 31, 2020, all of the Company's business was directly derived from US cannabis-related activities, based on the existing operations of the Company in Florida. As such, the Company's balance sheet and operating statement exposure to US cannabis-related activities is 100%.

Florida

The Company is licensed to operate as a "medical marijuana treatment center" under applicable Florida law pursuant to the terms of the license issued by the Florida Department of Health, Office of Medical Marijuana Use under the provisions of section 381.986, Florida Statutes. The Company operates the 387-acre Liberty 360 property in Gainesville, Florida where the Company cultivates and sells medical cannabis. Liberty has under contract approximately 275 full or part time staff through the State of Florida, including lab technicians, horticulturalists, operations, sales, marketing and manufacturing personnel. The Company began full production at its Liberty 360 location in Gainesville in fiscal 2019. The Company has opened 26 dispensaries to date throughout Florida, has lease agreements in place for another ten locations, and is further negotiating another seven.

Enforcement of United States Federal Laws

In the United States, cannabis is largely regulated at the state level. Notwithstanding the permissive regulatory environment of medical cannabis at the state level, and the increasing number of states with legal recreational frameworks, cannabis continues to be categorized as a Schedule I controlled substance under the CSA and as such, violates federal law in the United States. Senators Elizabeth Warren and Cory Gardner have introduced a bipartisan Senate bill titled "Strengthening the Tenth Amendment Through Entrusting States (STATES) Act" that would lift the Controlled Substance Act's restrictions on cannabis in states that have written their own laws. However, there can be no assurances as to when this bill will pass, or if it will pass at all. See "*Industry Trends and Risks*".

Medical cannabis is currently protected against enforcement by enacted legislation from United States

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

Congress in the form of the Rohrabacher-Blumenauer Amendment (as defined herein) which similarly prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the state level, subject to Congress restoring such funding. See "*United States Enforcement Proceedings*". Due to the ambiguity of the Sessions Memorandum in relation to medical cannabis, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law. See "*Industry Trends and Risks*".

Under U.S. federal law it may potentially be a violation of federal money laundering statutes for financial institutions to accept any proceeds from cannabis sales or any other Schedule I narcotics. Canadian banks are similarly reluctant to transact with cannabis companies, due to the uncertain legal and regulatory framework characterizing the industry at present. Banks and other financial institutions could be prosecuted and possibly convicted of money laundering for providing services to cannabis businesses. Under U.S. federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan, or any other service could be found guilty of money laundering or conspiracy. See "*Industry Trends and Risks*".

Further, violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of medical cannabis licenses in the United States, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. See "*Industry Trends and Risks*".

United States Enforcement Proceedings

The United States Congress has passed appropriations bills each of the last three years that included the Rohrabacher Amendment Title: H.R.2578 — Commerce, Justice, Science, and Related Agencies Appropriations Act, 2016 ("Rohrabacher-Blumenauer Amendment"), which by its terms does not appropriate any federal funds to the United States Department of Justice for the prosecution of medical cannabis offenses of individuals who are in compliance with state medical cannabis laws. Since it first passed as the Rohrabacher–Farr amendment in 2014, this measure has been renewed regularly with bipartisan support. It is currently in effect until September 30, 2020. American courts have construed these appropriations bills to prevent the federal government from prosecuting individuals when those individuals comply with state law. However, because this conduct continues to violate federal law, American courts have observed that should Congress at any time choose to appropriate funds to fully prosecute the CSA, any individual or business—even those that have fully complied with state law—could be prosecuted for violations of federal law. If Congress restores funding, the United States government could have the authority to prosecute individuals for violations of the law before it lacked funding under the CSA's five-year statute of limitations.

Ability to Access Public and Private Capital

The Company has historically, and continues to have, access to both public and private capital in Canada in order to support its continuing operations. The Company has had cannabis-related activities in the United States since its inception in July 2017 when the CSE approved the Business Combination and the resulting reverse takeover and listing of the Company's common shares. In addition, the Company had success completing private offerings in the past, including a May 2018 Bought Deal Offering which raised \$21.4 million of net proceeds for the Company, and has ongoing banking relationships with Alterna Savings a Canadian credit union based out of Ottawa, Ontario, and with First Federal Bank based out of Lake City, Florida. Although the Company has accessed private financing in the past, there is neither a broad nor deep pool of institutional capital that is available to cannabis license holders and license applicants. There

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

can be no assurance that additional financing, if raised privately, will be available to the Company when needed or on terms which are acceptable. The Company has never accessed public equity capital in the United States.

Regulation of Medical Cannabis in Florida

Liberty is licensed to produce and sell medical cannabis in the State of Florida through the Florida Department under the provisions of the Florida Legislation. The Florida Department of Health issued the License to Chestnut Hill Tree Farm on November 23, 2015 and Liberty acquired the rights to the License on May 23, 2017 via the exclusive management agreement entered between Liberty and Chestnut Hill Tree Farm. On September 28, 2017, the Florida Department approved the transfer of the License to Liberty Florida, which now solely owns and is entitled to utilize the License in Florida.

The License permits the sale of low-THC cannabis and medical marijuana with unlimited THC levels to treat a number of medical conditions in the State of Florida which are delineated in Florida Statutes section 381.986. Under the terms of the License, Liberty is permitted to sell medical cannabis only to qualified medical patients that are registered with the state. Only certified physicians who have successfully completed a medical cannabis educational program can register patients and their medical cannabis orders on the Florida Office of Medical Marijuana Use Registry. Liberty maintains an open and collaborative relationship with the Florida Department of Health and Liberty's operations are in full compliance with all laws and regulations.

Under the Liberty License, up until April 1, 2020 Liberty could operate up to 40 dispensaries statewide. Effective April 1, 2020 license holders can operate an unlimited number of dispensaries within the confines of the state of Florida. Currently, the dispensaries can be in any geographic location within the state as long as the local municipality's zoning regulations authorize such a use and is not within 500 feet of a K-12 school. In the State of Florida, only cannabis that is grown in the state can be sold in the state. As Florida is a vertically integrated system, Liberty (and other licensees) is required to cultivate, harvest, process and sell/dispense/deliver its own medical cannabis products. The State may also allow Liberty to make a wholesale purchase of medical cannabis from, or a distribution of medical cannabis to, another licensed medical marijuana treatment center within the state under limited circumstances such as a demonstrated crop failure. At the present time, Liberty's principal products include cannabis oil in capsule, oral solution, smokable flower, sublingual solution and vaporizer forms.

Regulatory Framework

The State of Florida Statutes 381.986(8)(a) provides a regulatory framework that requires licensed producers, which are statutorily defined as "Medical Marijuana Treatment Centers," to both cultivate, process and dispense medical cannabis in a vertically integrated marketplace.

Licensing Requirements

Licenses issued by the Florida Department are renewed biennially so long as the licensee meets requirements of the law and pays a renewal fee. Effective April 1, 2020 license holders can only own one vertical medical cannabis license and MMTCs can operate an unlimited number of dispensaries within the confines of the state of Florida.

Applicants must demonstrate (and licensed MMTCs must maintain) that: (i) they have been registered to do business in the State of Florida for the previous five years, (ii) they possess a valid certificate of registration issued by the Florida Department of Agriculture, (iii) they have the technical and technological ability to cultivate and produce cannabis, including, but not limited to, low-THC cannabis, (iv) they have the ability to secure the premises, resources, and personnel necessary to operate as an MMTC, (v) they have the ability to maintain accountability of all raw materials, finished products, and any byproducts to prevent diversion or unlawful access to or possession of these substances, (vi) they have an infrastructure reasonably located to dispense cannabis to registered qualified patients statewide or regionally as determined by the Department, (vii) they have the financial ability to maintain operations for the duration of

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

the two-year approval cycle, including the provision of certified financial statements to the Department, (viii) all owners, officers, board members and managers have passed a Level II background screening, inclusive of fingerprinting, and ensure that a medical director is employed to supervise the activities of the MMTC, and (ix) they have a diversity plan and veterans plan accompanied by a contractual process for establishing business relationships with veterans and minority contractors and/or employees.

Upon approval of the application by the Department, the applicant must post a performance bond of up to US\$5,000,000, which may be reduced by meeting certain criteria such as a minimum patient count.

Dispensary Requirements

An MMTC may not dispense more than a 70-day supply of cannabis. The MMTC employee who dispenses the cannabis must enter into the registry his or her name or unique employee identifier. The MMTC must verify that: (i) the qualified patient and the caregiver, if applicable, each has an active registration in the registry and active and valid medical cannabis use registry identification card, (ii) the amount and type of cannabis dispensed matches the physician certification in the registry for the qualified patient, and (iii) the physician certification has not already been filled. An MMTC may not dispense to a qualified patient younger than 18 years of age, only to such patient's caregiver. An MMTC may not dispense or sell any other type of cannabis, alcohol, or illicit drug-related product, except a cannabis delivery device as specified in the physician certification. An MMTC must, upon dispensing, record in the registry: (i) the date, time, quantity and form of cannabis dispensed, (ii) the type of cannabis delivery device dispensed, and (iii) the name and registry identification number of the qualified patient or caregiver to whom the cannabis delivery device was dispensed. An MMTC must ensure that patient records are not visible to anyone other than the patient, caregiver, and MMTC employees.

Security Requirements for Cultivation, Processing and Dispensing Facilities

With respect to security requirements for cultivation, processing and dispensing facilities, an MMTC must maintain a fully operational alarm system that secures all entry points and perimeter windows, and is equipped with motion detectors, pressure switches, and duress, panic and hold-up alarms. The MMTC must also have a 24-hour video surveillance system with specified features. MMTCs must retain video surveillance recordings for at least 45 days, or longer upon the request of law enforcement. An MMTC's outdoor premises must have sufficient lighting from dusk until dawn.

An MMTC's dispensing facilities must include a waiting area with sufficient space and seating to accommodate qualified patients and caregivers and at least one private consultation area and such facilities may not display products or dispense cannabis or cannabis delivery devices in the waiting area and may not dispense cannabis from its premises between the hours of 9:00 p.m. and 7:00 a.m. but may perform all other operations and deliver cannabis to qualified patients 24-hours a day.

Transportation and Storage Requirements

Cannabis must be stored in a secured, locked room or a vault. An MMTC must have at least two employees, or two employees of a security agency, on the premises at all times where cultivation, processing, or storing of cannabis occurs. MMTC employees must wear a photo identification badge and visitors must wear a visitor pass at all times on the premises. An MMTC must report to law enforcement within 24 hours after the MMTC is notified of or becomes aware of the theft, diversion or loss of cannabis. A cannabis transportation manifest must be maintained in any vehicle transporting cannabis or a cannabis delivery device. The manifest must be generated from the MMTC's seed-to-sale tracking system and must include the: (i) departure date and time, (ii) name, address, and license number of the originating MMTC, (iii) name and address of the recipient, (iv) quantity and form of any cannabis or cannabis delivery device being transported, (v) arrival date and time, (vi) delivery vehicle make and model and license plate number; and (vii) name and signature of the MMTC employees delivering the product. Further, a copy of the transportation manifest must be provided to each individual, MMTC that receives a delivery. MMTCs must retain copies of all cannabis transportation manifests for at least three years. Cannabis and cannabis

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

delivery devices must be locked in a separate compartment or container within the vehicle and employees transporting cannabis or cannabis delivery devices must have their employee identification on them at all times. Lastly, at least two people must be in a vehicle transporting cannabis or cannabis delivery devices, and at least one person must remain in the vehicle while the cannabis or cannabis delivery device is being delivered.

Department Inspections

The Florida Department shall conduct announced or unannounced inspections of MMTCs to determine compliance with the laws and rules. The Florida Department shall inspect an MMTC upon receiving a complaint or notice that the MMTC has dispensed cannabis containing mold, bacteria, or other contaminants that may cause an adverse effect to humans or the environment. The Florida Department shall conduct at least a biennial inspection of each MMTC to evaluate the MMTC's records, personnel, equipment, security, sanitation practices, and quality assurance practices.

Compliance of United States Operations

Liberty is in compliance with applicable licensing requirements and the regulatory framework enacted by the State of Florida. As further detailed above, Liberty is licensed to operate as a MMTC under applicable Florida law pursuant to the terms of the Florida License. The Florida License grants Liberty the authority to possess, cultivate, process, dispense and sell medical cannabis in the State of Florida. Liberty has not experienced any non-compliance nor has been subject to any notices of violation by the Department. As at May 31, 2020, Liberty maintains banking relationships in the United States with First Federal Bank in Florida, and Alterna Savings in Canada. The Company also engages armored car services as a custodian of cash and deposits, which are delivered to the Federal Reserve Bank on behalf of the Company and then reflected in the Company's First Federal bank account.

The Company has a full time Compliance Officer on staff in Florida whose responsibilities are to monitor the day to day activities of staff, including ensuring that the established standard operating procedures are being adhered to at each stage of the cultivation, processing and distribution cycle, to identify any non-compliance matters and to put in place the necessary modifications to ensure compliance. The Compliance Officer performs monthly, unannounced audits against the Company's established standard operating procedures and state regulations. Each employee is provided with an employee handbook outlining the standard operating procedures and state regulations upon hiring and is then provided with one on one quality and regulatory training by the Compliance Officer. The Company has 24-hour surveillance of every room, including greenhouses, in which cannabis is cultivated, processed, and stored. This footage is kept for at least 45 days as per the requirements of the Department. Security officers also perform a walk through every four hours to check each room and look for unusual activity. The Company also utilizes state approved software for tracking cannabis inventory from seed to sale. The Compliance Officer's duties also include ongoing education of staff on the state regulations. State inspections to date have not resulted in any material non-compliance issues.

The Company has worked with its legal advisors in Florida to implement, and is working with legal advisors to implement measures designed to ensure compliance with applicable state laws in the United States on an ongoing basis, including:

- weekly correspondence and updates with advisors;
- development of standard operating procedures with respect to cultivation, processing and distribution;
- ongoing monitoring of compliance with operating procedures and regulations by on-site management;
- appropriate employee training for all standard operating procedures; and
- subscription to monitoring programs to ensure compliance with the FCEN Memo (as defined herein).

While the Company's business activities are compliant with applicable state and local law, such activities

remain illegal under the federal laws of the United States. See "*Industry Trends and Risks*".

INDUSTRY TRENDS AND RISKS

The Company's overall performance and results of operations are subject to a number of risks and uncertainties, of which the below are considered to be the Company's principal risks. For a more detailed and complete discussion of economic, industry and risk factors of the Company, please see the "Risk Factors" section in our most recent Annual Information Form, dated July 1, 2019.

Risk Factors Related to the United States

While cannabis is legal in many US state jurisdictions, it continues to be a controlled substance under the United States Federal Controlled Substances Act.

Investors are cautioned that in the United States, cannabis is largely regulated at the state level. Notwithstanding the permissive regulatory environment of medical cannabis at the state level, and the increasing number of states with legal recreational frameworks, cannabis continues to be categorized as a Schedule I controlled substance under the CSA and as such, violates federal law in the United States. Senators Elizabeth Warren and Cory Gardner have introduced a bipartisan Senate bill titled "Strengthening the Tenth Amendment Through Entrusting States (STATES) Act" that would lift the Controlled Substance Act's restrictions on cannabis in states that have written their own laws. However, there can be no assurances as to when this bill will pass, or if it will pass at all.

The United States Congress has passed appropriations bills in 2019 and each of the last three years that have not appropriated funds for prosecution of cannabis offenses of individuals who are in compliance with state medical cannabis laws. American courts have construed these appropriations bills to prevent the federal government from prosecuting individuals when those individuals comply with state law. However, because this conduct continues to violate federal law, American courts have observed that should Congress at any time choose to appropriate funds to fully prosecute the CSA, any individual or business—even those that have fully complied with state law—could be prosecuted for violations of federal law. And if Congress restores funding, the government will have the authority to prosecute individuals for violations of the law before it lacked funding under the CSA's five-year statute of limitations.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of medical cannabis licenses in the United States, the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

Liberty derives 100% of its revenues from the cannabis industry in Florida, which industry is illegal under the federal laws of the United States. While the Company's business activities are compliant with applicable state and local law, such activities remain illegal under the federal laws of the United States. The enforcement of relevant federal laws is a significant risk.

The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined.

As a result of the conflicting views between state legislatures and the federal government regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation and regulation. The response to this inconsistency was addressed in the Cole Memorandum addressed to

LIBERTY HEALTH SCIENCES INC. MANAGEMENT'S DISCUSSION & ANALYSIS

all United States district attorneys acknowledging that, notwithstanding the designation of cannabis as a controlled substance at the federal level in the United States, several US states have enacted laws relating to cannabis for medical purposes.

The Cole Memorandum outlined certain priorities for the Department of Justice relating to the prosecution of cannabis offenses. In particular, the Cole Memorandum noted that in jurisdictions that have enacted laws legalizing cannabis in some form and that have also implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale and possession of cannabis, conduct in compliance with those laws and regulations is less likely to be a priority at the federal level. Notably, however, the Department of Justice has never provided specific guidelines for what regulatory and enforcement systems it deems sufficient under the Cole Memorandum standard.

In light of limited investigative and prosecutorial resources, the Cole Memorandum concluded that the Department of Justice should be focused on addressing only the most significant threats related to cannabis. States where medical cannabis had been legalized were not characterized as a high priority. In March 2017, newly appointed Attorney General Jeff Sessions again noted limited federal resources and acknowledged that much of the Cole Memorandum had merit; however, he disagreed that it had been implemented effectively and, on January 4, 2018, Attorney General Jeff Sessions issued the Sessions Memorandum, which rescinded the Cole Memorandum. The Sessions Memorandum rescinded previous nationwide guidance specific to the prosecutorial authority of United States Attorneys relative to cannabis enforcement on the basis that they are unnecessary, given the well-established principles governing federal prosecution that are already in place. Those principles are included in chapter 9.27.000 of the United States Attorneys' Manual and require federal prosecutors deciding which cases to prosecute to weigh all relevant considerations, including federal law enforcement priorities set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community. To the knowledge of management of the Company, there have not been any additional statements or guidance made by federal authorities or prosecutors regarding the risk of enforcement action in Florida.

As a result of the Sessions Memorandum, federal prosecutors are now free to utilize their prosecutorial discretion to decide whether to prosecute cannabis activities despite the existence of state-level laws that may be inconsistent with federal prohibitions. No direction was given to federal prosecutors in the Sessions Memorandum as to the priority they should ascribe to such cannabis activities, and as a result it is uncertain how active federal prosecutors are or will be in relation to such activities. Furthermore, the Sessions Memorandum did not discuss the treatment of medical cannabis by federal prosecutors.

Medical cannabis is currently protected against enforcement by enacted legislation from United States Congress in the form of the Rohrabacher-Blumenauer Amendment which similarly prevents federal prosecutors from using federal funds to impede the implementation of medical cannabis laws enacted at the state level, subject to Congress restoring such funding. Subsequent to the issuance of the Sessions Memorandum on January 4, 2018, the United States Congress passed its omnibus appropriations bill, SJ 1662, which for the fourth consecutive year contained the Rohrabacher-Blumenauer Amendment language (referred to in 2018 as the Rohrabacher-Leahy Amendment) and continued the protections for the medical cannabis marketplace and its lawful participants from interference by the Department of Justice up and through the 2018 appropriations deadline of September 30, 2018. These protections were subsequently extended through December 7, 2018 and January 25, 2019 as part of short-term continuations of appropriations. On February 15, 2019, the amendment was renewed as part of an omnibus appropriations bill in effect until September 30, 2019. See "*United States Enforcement Proceedings*". The amendment is currently in effect through September 30, 2020. Due to the ambiguity of the Sessions Memorandum in relation to medical cannabis, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law in the future.

Such potential proceedings could involve significant restrictions being imposed upon the Company or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on the Company's business, revenues, operating results and financial condition as well as the

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

Company's reputation, even if such proceedings were concluded in favor of the Company. In the extreme case, such proceedings could ultimately involve the prosecution of key executives of the Company or the seizure of corporate assets; however, as of the date hereof, the Company believes and has obtained legal advice in respect thereof that proceedings of this nature are remote.

The Company's investments in the United States are subject to applicable anti-money laundering laws and regulations.

The Company is subject to a variety of laws and regulations domestically and in the United States that involve money laundering, financial recordkeeping and proceeds of crime, including the *Currency and Foreign Transactions Reporting Act of 1970* (commonly known as the *Bank Secrecy Act*), as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the *Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada)*, as amended and the rules and regulations thereunder, the *Criminal Code (Canada)* and any related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the United States and Canada.

In February 2014, the FCEN issued the FCEN Memo providing instructions to banks seeking to provide services to cannabis-related businesses. The FCEN Memo states that in some circumstances, it is permissible for banks to provide services to cannabis-related businesses without risking prosecution for violation of federal money laundering laws. It refers to supplementary guidance that Deputy Attorney General Cole issued to federal prosecutors relating to the prosecution of money laundering offenses predicated on cannabis-related violations of the CSA. It is unclear at this time whether the current administration will follow the guidelines of the FCEN Memo.

In the event that any of the Company's operations, or any proceeds thereof, any dividends or distributions therefrom, or any profits or revenues accruing from such operations in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under one or more of the statutes noted above or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, affect other distributions or subsequently repatriate such funds back to Canada. Furthermore, while the Company has no current intention to declare or pay dividends on its common shares in the foreseeable future, in the event that a determination was made that the Company's proceeds from operations (or any future operations or investments in the United States) could reasonably be shown to constitute proceeds of crime, the Company may decide or be required to suspend declaring or paying dividends without advance notice and for an indefinite period of time.

The Company's investments in the United States may be subject to heightened scrutiny.

For the reasons set forth above, the Company's existing operations in the United States, and any future operations or investments, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company's ability to operate or invest in the United States or any other jurisdiction, in addition to those described herein.

Given the heightened risk profile associated with cannabis in the United States, the Canadian Depository for Securities ("CDS") may implement procedures or protocols that would prohibit or significantly curtail the ability of CDS to settle trades for cannabis companies that have cannabis businesses or assets in the United States. On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of a Memorandum of Understanding ("TMX MOU") with Aequitas NEO Exchange Inc., the CSE, the Toronto Stock Exchange and the TSX Venture Exchange. The TMX MOU outlines the parties' understanding of Canada's regulatory framework applicable to the rules, procedures and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis-related activities in the United States. The TMX MOU confirms, with respect to the clearing of listed securities, that CDS relies on the exchanges to review the conduct of listed issuers.

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

As a result, there is no CDS ban on the clearing of securities of issuers with cannabis-related activities in the United States. However, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented, it would have a material adverse effect on the ability of holders of common shares to make and settle trades. In particular, the common shares would become highly illiquid until an alternative was implemented, and investors would have no ability to affect a trade of the common shares through the facilities of a stock exchange.

In light of the political and regulatory uncertainty surrounding the treatment of U.S. cannabis-related activities, including the rescission of the Cole Memorandum discussed above, on February 8, 2018, the Canadian Securities Administrators revised their previously released Staff Notice setting out their disclosure expectations for specific risks facing issuers with cannabis-related activities in the United States. The Staff Notice confirms that a disclosure-based approach remains appropriate for issuers with U.S. cannabis-related activities. The Staff Notice includes additional disclosure expectations that apply to all issuers with U.S. cannabis-related activities, including those with direct and indirect involvement in the cultivation and distribution of cannabis, as well as issuers that provide goods and services to third parties involved in the U.S. cannabis industry. The Company views the Staff Notice favorably, as it provides increased transparency and greater certainty regarding the views of its exchange and its regulator of existing operations and strategic business plan as well as the Company's ability to pursue further investment and opportunities in the United States.

Government policy changes or public opinion may also result in a significant influence over the regulation of the cannabis industry in Canada, the United States or elsewhere. A negative shift in the public's perception of medical cannabis in the United States or any other applicable jurisdiction could affect future legislation or regulation. Among other things, such a shift could cause state jurisdictions to abandon initiatives or proposals to legalize medical cannabis, thereby limiting the number of new state jurisdictions into which the Company could expand. Additionally, due to the uncertain regulatory landscape, the Company's third-party suppliers, manufacturers and contractors may elect, at any time, to decline or withdraw services necessary for the Company's operations. Any inability to fully implement the Company's expansion strategy may have a material adverse effect on the Company's business, financial condition and results of operations.

Regulatory risks

The activities of the Company are subject to regulation by governmental authorities. The Company's business objectives are in part contingent upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products in each jurisdiction in which it operates. Liberty cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the business, results of operations and financial condition of the Company. New risks may emerge, and management may not be able to predict all such risks or be able to predict how such risks may result in actual results differing from the results contained in any forward-looking statements.

Furthermore, although the operations of the Company are currently carried out in accordance with all applicable rules and regulations, no assurance can be given that new rules and regulations will not be enacted or that existing rules and regulations will not be applied in a manner which could limit or curtail the Company's ability to import, distribute or, in the future, produce cannabis. Amendments to current laws and regulations governing the importation, distribution, transportation and/or production of cannabis, or more stringent implementation thereof could have a substantial adverse impact on the Company.

Because of the conflicting views between state legislatures and the federal government of the United States regarding cannabis, investments in cannabis businesses in the United States are subject to inconsistent legislation, regulation, and enforcement. Unless and until the United States Congress amends the United States Controlled Substances Act with respect to cannabis or the Drug Enforcement Agency reschedules

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

or de-schedules cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current federal law, which would adversely affect the current and future operations of the Company in the United States. As a result of the tension between state and federal law, there are a number of significant risks associated with the Company's existing and future operations in the United States.

Legislative or regulatory reform and compliance

The Company's operations are subject to a variety of laws, regulations, guidelines and policies relating to the manufacture, import management, packaging/labelling, processing, production, advertising, sale, transportation, storage and disposal of medical cannabis, but also including laws and regulations relating to drugs, controlled substances, health and safety, relationships with health care providers, the conduct of operations and the protection of the environment.

The industry is subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The marketability of any product may be affected by numerous factors that are beyond the control of the Company's investments and which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce the profitability of Company's operations and could make the Company's operations uneconomic. The industry is also subject to numerous legal challenges, which may significantly affect the financial condition of market participants and which cannot be reliably predicted.

The Company also incurs ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional costs for corrective measures, penalties or in restrictions on operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company's investments and, therefore, on the Company's prospective returns. Further, the Company may be subject to a variety of claims and lawsuits. Adverse outcomes in some or all of these claims may result in significant monetary damages or injunctive relief that could adversely affect the Company's ability to conduct its business. The litigation and other claims are subject to inherent uncertainties and management's view of these matters may change in the future. A material adverse impact on our financial statements also could occur for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.

The commercial medical and recreational cannabis industry is in its infancy and the Company anticipates that such regulations will be subject to change as the state and federal government monitors licensed producers in action. The Company will continue to monitor compliance on an ongoing basis in accordance with all applicable internal and external policies and procedures, which can be found in the Company's initial application for licensure and in Company manuals and protocols.

Reliance on third-party suppliers, manufacturers and contractors

The Company maintains a full supply chain for the provision of products and services to the regulated cannabis industry. Due to the uncertain regulatory landscape for regulating cannabis in Canada and the United States, the Company's third-party suppliers, manufacturers and contractors may elect, at any time, to decline or withdraw services necessary for the Company's operations. Loss of these suppliers, manufacturers and contractors may have a material adverse effect on the Company's business and operational results.

Banking

Since the cultivation, distribution and possession of cannabis is currently illegal under U.S. federal law, it is possible that banks may refuse to open bank accounts for the deposit of funds from businesses involved

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

with the cannabis industry. The inability to open bank accounts with certain institutions could materially and adversely affect the business of the Company. See *Issuers with U.S. Cannabis Related Business – Ability to Access Public and Private Capital* and *Issuers with U.S. Cannabis Related Business – Compliance of United States Operations*.

Operation permits and authorizations

The Company's investments may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate their respective businesses. In addition, the Company's investments may not be able to comply fully with the wide variety of laws and regulations applicable to the cannabis industry. Failure to comply with or to obtain the necessary licenses, permits, authorizations or accreditations could result in restrictions on an investment's ability to operate in the cannabis industry, which could have a material adverse effect on the Company's business.

Liability, enforcement complaints, etc.

The Company's participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by various federal, state, or local governmental authorities against the Company or its investments. Litigation, complaints, and enforcement actions involving either of the Company or its investments could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on the Company's future cash flows, earnings, results of operations and financial condition.

Reliance on License

Liberty's ability to grow, store and sell medical cannabis and cannabis oil in the State of Florida is dependent on maintaining its Florida License in good standing with the Florida Department. Failure to comply with the requirements of the Florida License, or any failure to maintain any licenses held would have a material adverse impact on the business, financial condition and operating results of the Company. The Company's licenses are currently in good standing and the Company remains fully compliant with the associated state laws and regulations.

Risks Inherent in an Agricultural Business

Liberty's business involves the growing of medical cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although Liberty expects that any such growing will be completed indoors under climate-controlled conditions, there can be no assurance that natural elements will not have a material adverse effect on any such future production.

Limited Operating History

Since its inception, Liberty's activities have been funded through financing activities. Starting with the quarter ended August 31, 2019, Liberty began also funding activities from cash from operations. Liberty is subject to many of the risks common to early-stage enterprises, including challenges related to laws, regulations, licensing, integrating and retaining qualified employees; making effective use of limited resources; achieving market acceptance of existing and future solutions; competing against companies with greater financial and technical resources; acquiring and retaining customers; and developing new solutions. There is no assurance that Liberty will be successful in achieving a return on shareholders' investment and the likelihood of success must be considered in light of the early stage of operations.

Securing Additional Financing to Fund Operations and Meet Consumer Demand

There is no guarantee that the Company will be able to achieve its business objectives. The continued development of the Company may require additional financing. The failure to raise such capital could result

LIBERTY HEALTH SCIENCES INC.
MANAGEMENT'S DISCUSSION & ANALYSIS

in the delay or indefinite postponement of current business objectives or the Company ceasing to carry on business. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favorable to the Company. See *Issuers with U.S. Cannabis Related Businesses – Ability to Access Public and Private Capital*. In addition, from time to time, Liberty may enter into transactions to acquire assets or the shares of other corporations. These transactions may be financed wholly or partially with debt, which may increase the Company's debt levels above industry standards. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions. Debt financings may also contain provisions which, if breached, may entitle lenders or their agents to accelerate repayment of loans and/or realize upon security over the assets of the Company, and there is no assurance that the Company would be able to repay such loans in such an event or prevent the enforcement of security granted pursuant to such debt financing. The Company may require additional financing to fund its operations until positive cash flow is achieved.

Regulatory or Agency Proceedings, Investigations and Audits

The Company's business requires compliance with many laws and regulations. Failure to comply with these laws and regulations could subject the Company to regulatory or agency proceedings or investigations and could also lead to damage awards, fines and penalties. Liberty may become involved in a number of government or agency proceedings, investigations and audits. The outcome of any regulatory or agency proceedings, investigations, audits, and other contingencies could harm the Company's reputation, require the Company to take, or refrain from taking, actions that could harm its operations or require Liberty to pay substantial amounts of money, harming its financial condition. There can be no assurance that any pending or future regulatory or agency proceedings, investigations and audits will not result in substantial costs or a diversion of management's attention and resources or have a material adverse impact on the Company's business, financial condition and results of operation.

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating and the value of the Common Shares and could use significant resources. Even if Liberty is involved in litigation and wins, litigation can redirect significant Company resources, including the time and attention of management and available working capital. Litigation may also create a negative perception of the Company's brand. See note regarding litigation in "Commitments and Contingencies".